News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
FDA suspends license for chikungunya vaccine Ixchiq over serious safety concerns
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.
MedPage Today on MSN1d
In Abrupt Reversal, FDA Yanks Ixchiq Vaccine Over Safety Concern
According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...
The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.
Dr. Vinay Prasad, an oncologist who was a fierce critic of COVID vaccine and mask mandates, was appointed in May.
Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...
A Food and Drug Administration official who stepped down less than two weeks ago is getting his job back as the agency's top vaccine regulator.
IFLScience on MSN5d
COVID-19 “Vaccine Alternative” Injection Could Be On Fast-Track To Approval From FDA
Pharma company Invivyd, Inc. just announced it is working with the US Food and Drug Administration (FDA) on a pathway to ...
As a summer COVID-19 surge hits Michigan, unanswered questions abound about eligibility, insurance coverage and when new ...
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback